ANX Mast Therapeutics, Inc.

SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today announced that senior management will make presentations at three conferences during the week of November 7th: * Evan M. Levine, president and CEO, will present at the Rodman and Renshaw Techvest 7th Annual Healthcare Conference on Tuesday, November 8 at 9:45 a.m. Eastern Time. This conference will be held at the Palace Hotel in New York. For more information about this conference visit http://www.rodmanandrenshaw.com/. * Brian M. Culley, vice president of business development, will present at the Bio-Europe 2005 11th Annual International Partnering Conference on Tuesday, November 8 at 8:45 a.m. Central European Time (2:45 a.m. Eastern Time). This conference will be held at the Congress Center in Dresden, Germany. For more information on this conference visit http://www.bio.org/. * Mr. Levine will also present at the CIBC World Markets 16th Annual Healthcare Conference on Wednesday, November 9 at 11:00 a.m. Eastern Time. This conference will be held at The Waldorf-Astoria Hotel in New York. For more information about this conference visit http://www.conferences.cibcwm.com/health05/. A live slide and audio webcast of Mr. Levine's presentation at the CIBC World Markets Healthcare Conference will be available via the Internet by visiting the "Investors" section of the Company's Web site at http://www.adventrx.com/investors/events.htm. The presentation and link to the archived webcast will be available on the ADVENTRX Web site for 14 days. About ADVENTRX ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments that improve the performance and safety of existing drugs by addressing significant problems such as drug metabolism, toxicity, bioavailability and resistance. The Company's lead compound, CoFactor(TM), is a biomodulator of 5-fluorouracil (5-FU), a widely used cancer chemotherapy. CoFactor is currently being tested with 5-FU in Phase II and Phase IIb clinical trials as a first line treatment of metastatic colorectal cancer. In addition, CoFactor has received clearance under a special protocol assessment from the US Food and Drug Administration (FDA) to begin a Phase III pivotal clinical trial for metastatic colorectal cancer. More information can be found on the Company's Web site at http://www.adventrx.com/. Forward Looking Statements Regarding ADVENTRX This press release contains forward-looking statements, within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, regarding ADVENTRX. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the FDA and other regulatory agencies. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements regarding ADVENTRX, see the section titled "Risk Factors" in ADVENTRX's last quarterly report on Form 10-Q, as well as other reports that ADVENTRX files from time to time with the Securities and Exchange Commission. All forward-looking statements regarding ADVENTRX are qualified in their entirety by this cautionary statement. ADVENTRX undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof. DATASOURCE: ADVENTRX Pharmaceuticals, Inc. CONTACT: Andrea Lynn of ADVENTRX Pharmaceuticals, Inc., +1-858-552-0866 Web site: http://www.rodmanandrenshaw.com/ Web site: http://www.bio.org/ Web site: http://www.adventrx.com/investors/events.htm Web site: http://www.adventrx.com/ Company News On-Call: http://www.prnewswire.com/comp/920134.html

Copyright